Neurocognitive dysfunction in hematopoietic cell transplant recipients: Expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT

David Buchbinder, Debra Lynch Kelly, Rafael F. Duarte, Jeffery J. Auletta, Neel Bhatt, Michael Byrne, Zachariah Defilipp, Melissa Gabriel, Anuj Mahindra, Maxim Norkin, Helene Schoemans, Ami J. Shah, Ibrahim Ahmed, Yoshiko Atsuta, Grzegorz W. Basak, Sara Beattie, Sita Bhella, Christopher Bredeson, Nancy Bunin, Jignesh DalalAndrew Daly, James Gajewski, Robert Peter Gale, John Galvin, Mehdi Hamadani, Robert J. Hayashi, Kehinde Adekola, Jason Law, Catherine J. Lee, Jane Liesveld, Adriana K. Malone, Arnon Nagler, Seema Naik, Taiga Nishihori, Susan K. Parsons, Angela Scherwath, Hannah Lise Schofield, Robert Soiffer, Jeff Szer, Ida Twist, Anne B. Warwick, Baldeep M. Wirk, Jean Yi, Minoo Battiwalla, Mary D.E. Flowers, Bipin Savani, Bronwen E. Shaw

Research output: Contribution to journalReview article

15 Scopus citations

Abstract

Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and non-malignant diseases. Despite increasing survival rates, long-term morbidity following HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction following HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction following HCT. In this review, we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and to help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Lastly, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae following HCT.

Original languageEnglish
Pages (from-to)535-555
Number of pages21
JournalBone Marrow Transplantation
Volume53
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint Dive into the research topics of 'Neurocognitive dysfunction in hematopoietic cell transplant recipients: Expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT'. Together they form a unique fingerprint.

  • Cite this

    Buchbinder, D., Kelly, D. L., Duarte, R. F., Auletta, J. J., Bhatt, N., Byrne, M., Defilipp, Z., Gabriel, M., Mahindra, A., Norkin, M., Schoemans, H., Shah, A. J., Ahmed, I., Atsuta, Y., Basak, G. W., Beattie, S., Bhella, S., Bredeson, C., Bunin, N., ... Shaw, B. E. (2018). Neurocognitive dysfunction in hematopoietic cell transplant recipients: Expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplantation, 53(5), 535-555. https://doi.org/10.1038/s41409-017-0055-7